UNSPSC 51113208: Triaziquone

This classification denotes an ethylenimine compound with the molecular formula C12H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F3D5D9P25I, chemically known as 2,3,5-tris-ethyleniminoquinone-(1,4) but more generally known as triaziquone, which bears US NIH Compound Identifier 6235. European Medicines Agency schedules Triaziquone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11257MIG. The term TRIAZIQUONE is an International Non-Proprietary Name.

UNSPSC 51113208 Triaziquone is a Commodity code representing a specific pharmaceutical chemical compound. Based on recent state and local procurement activity, the code captures purchases of triaziquone and related pharmaceutical precursor chemicals by state health agencies pursuing direct-to-manufacturer pharmacy benefit programs and therapeutic drug sourcing initiatives. State health and human services departments are the primary issuing bodies under this code, with procurement focused on establishing direct supply relationships and cost-management mechanisms that bypass traditional pharmacy benefit managers and group purchasing organizations.

The Texas Health and Human Services Commission issued RFI No. HHS0017013 in April 2026 seeking vendor capabilities for implementing direct-to-manufacturer prescription programs that could encompass chemical pharmaceuticals like triaziquone. The information-gathering phase targets vendors with experience in direct contracting for self-insured employers and government health plans, negotiated net pricing models, and outcomes-based agreements. No recent opportunities beyond the Texas RFI appear in the current record, limiting visibility into geographic spread or issuing-body concentration across other states or municipalities. The exploratory nature of the Texas solicitation suggests early-stage market development rather than mature procurement volume under this code.